Phase 2 Study of Imatinib in Children with Neurofibromatosis and Airway Tumors
The purpose of this study is to look at a subset of plexiform neurofibromas and determine if the airway tumors are more sensitive to imatinib therapy.
The purpose of this study is to determine if NF1 associated pediatric airway-related plexiform neurofibromas represent a subset of plexiform neurofibromas with an inherent sensitivity to imatinib therapy and if imatinib therapy will show efficacy by improving respiratory function as assessed by pulmonary function tests and sleep study evaluations as children with airway tumors.
- IRB Number: 1505569560
- Research Study Identifier: TX5482
- Principal Investigator: Kent Robertson, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required